Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
Home News Retinal imaging specialist targets US growth following £1.3m fundraise

Retinal imaging specialist targets US growth following £1.3m fundraise

by wrich

Conal Harte appointed as CEO to accelerate commercialisation of epiCam 

Fife-based retinal imaging company epipole is set to grow its presence within the global ophthalmic imaging market after raising £1.3m in new investment.   

The company’s handheld epiCam enables clinicians to record epiStreams – scans of the retina using real-time video – from which high-quality images can be extracted for further examination. 

epipole has also appointed experienced med-tech executive Conal Harte as CEO from Össur, a leading global orthopaedics company, where he served as Managing Director Emerging Markets. Harte replaces Founder Craig Robertson, who moves to the position of Chief Technology Officer where he will develop further applications for epipole’s patented technology. 

Following the latest round of investment, further recruitment has also been initiated in the US to support the company’s product launch there and early commercialization within primary care optometry and general ophthalmology practices.  

epipole Chairman Ian Stevens said: “I am pleased to welcome Conal to the company. He joins at a crucial moment in our development and brings significant commercial experience of growing disruptive medical technologies in international markets.” 

Conal Harte said: “I am delighted to have the opportunity to join the epipole team at such an exciting time. Our unique approach to retinal imaging will help our clinician customers deliver an outstanding level of eye care to their patients through a market-leading technology that delivers exceptional imaging in a powerful, portable and low-cost device. This latest investment round will kickstart our US growth ambitions.” 

The investment fundraise was led by Greenwood Way Capital and supported by Scottish Enterprise. epipole was advised by Catherine Feechan, a partner at law firm Davidson Chalmers Stewart.